Literature DB >> 9109057

Chitosan as a nasal delivery system: the effect of chitosan solutions on in vitro and in vivo mucociliary transport rates in human turbinates and volunteers.

T J Aspden1, J D Mason, N S Jones, J Lowe, O Skaugrud, L Illum.   

Abstract

In these studies, we examined the effect on mucociliary transport rates (MTR) of various 0.25% (w/v) chitosan solutions applied to human nasal tissue both ex vivo and in vivo. In the first study a range of chitosans with different molecular weights were applied to freshly amputated human nasal turbinates, and their effect on MTR was recorded. The transient inhibitory effect on turbinate MTR that was found for most of the chitosan preparations showed a marked dependence on the volume of chitosan solution applied and the molecular weight of the chitosan tested. The higher the molecular weight of the chitosan and the more chitosan applied, the longer the original MTR was depressed. A small scale human trial, investigating the effect of chitosan glutamate, on saccharin clearance times, was also undertaken. The study showed that a once daily application of a 0.25% solution of the chitosan for 7 days had no effect on either saccharin clearance times or nasal histology as examined by light microscopy.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9109057     DOI: 10.1021/js960182o

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  28 in total

1.  Protective levels of diphtheria-neutralizing antibody induced in healthy volunteers by unilateral priming-boosting intranasal immunization associated with restricted ipsilateral mucosal secretory immunoglobulin a.

Authors:  Kingston H G Mills; Catherine Cosgrove; Edel A McNeela; Amy Sexton; Rafaela Giemza; Inderjit Jabbal-Gill; Anne Church; Wu Lin; Lisbeth Illum; Audino Podda; Rino Rappuoli; Mariagrazia Pizza; George E Griffin; David J M Lewis
Journal:  Infect Immun       Date:  2003-02       Impact factor: 3.441

Review 2.  Absorption enhancers for nasal drug delivery.

Authors:  Stanley S Davis; Lisbeth Illum
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 3.  Polymeric carriers for gene delivery: chitosan and poly(amidoamine) dendrimers.

Authors:  Qingxing Xu; Chi-Hwa Wang; Daniel Wayne Pack
Journal:  Curr Pharm Des       Date:  2010-07       Impact factor: 3.116

Review 4.  Chitosan: a promising safe and immune-enhancing adjuvant for intranasal vaccines.

Authors:  Alan Smith; Michael Perelman; Michael Hinchcliffe
Journal:  Hum Vaccin Immunother       Date:  2013-12-17       Impact factor: 3.452

5.  Intranasal vaccination with chitosan-DNA nanoparticles expressing pneumococcal surface antigen a protects mice against nasopharyngeal colonization by Streptococcus pneumoniae.

Authors:  Jianghong Xu; Wenjia Dai; Zhengmin Wang; Bing Chen; Zhongming Li; Xiaoyong Fan
Journal:  Clin Vaccine Immunol       Date:  2010-11-03

6.  Carbohydrate biopolymers enhance antibody responses to mucosally delivered vaccine antigens.

Authors:  A Bacon; J Makin; P J Sizer; I Jabbal-Gill; M Hinchcliffe; L Illum; S Chatfield; M Roberts
Journal:  Infect Immun       Date:  2000-10       Impact factor: 3.441

Review 7.  Chitosan and its use as a pharmaceutical excipient.

Authors:  L Illum
Journal:  Pharm Res       Date:  1998-09       Impact factor: 4.200

8.  Induction of protective serum meningococcal bactericidal and diphtheria-neutralizing antibodies and mucosal immunoglobulin A in volunteers by nasal insufflations of the Neisseria meningitidis serogroup C polysaccharide-CRM197 conjugate vaccine mixed with chitosan.

Authors:  Zhiming Huo; Ruchi Sinha; Edel A McNeela; Ray Borrow; Rafaela Giemza; Catherine Cosgrove; Paul T Heath; Kingston H G Mills; Rino Rappuoli; George E Griffin; David J M Lewis
Journal:  Infect Immun       Date:  2005-12       Impact factor: 3.441

9.  Preparation of chitosan-polyaspartic acid-5-fluorouracil nanoparticles and its anti-carcinoma effect on tumor growth in nude mice.

Authors:  Dan-Ying Zhang; Xi-Zhong Shen; Ji-Yao Wang; Ling Dong; Yong-Li Zheng; Li-Li Wu
Journal:  World J Gastroenterol       Date:  2008-06-14       Impact factor: 5.742

10.  Chitosan Interferon-gamma Nanogene Therapy for Lung Disease: Modulation of T-Cell and Dendritic Cell Immune Responses.

Authors:  Xiaoyuan Kong; Gary R Hellermann; Weidong Zhang; Prasanna Jena; Mukesh Kumar; Aruna Behera; Sumita Behera; Richard Lockey; Shyam S Mohapatra
Journal:  Allergy Asthma Clin Immunol       Date:  2008-09-15       Impact factor: 3.406

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.